Mycosis Fungoides, Sezary Syndrome
Conditions
Keywords
Poteligeo, mycosis fungoides, Sezary syndrome
Brief summary
The purpose of this surveillance is to assess the safety and efficacy of Poteligeo Inj. 20 mg (mogamulizumab) in routine clinical settings.
Detailed description
This post-marketing surveillance (PMS) is designed as an all-case investigation in accordance with the Korean Ministry of Food and Drug Safety (MFDS) re-examination requirements. It targets adult patients with mycosis fungoides (MF) or Sézary syndrome (SS) who have received at least one prior systemic therapy and are treated with mogamulizumab (POTELIGEO® Injection 20 mg) under the approved indication in Korea. Primary Objective: To assess the safety of mogamulizumab for patients treated under the approved indication in Korea. Secondary Objective: To assess the effectiveness of mogamulizumab for patients treated under the approved indication in Korea. Exploratory Objective: To perform additional subgroup and exploratory analyses of effectiveness, including evaluation in special populations such as elderly patients, patients with renal or hepatic impairment, and those with a history of hematopoietic stem cell transplantation, treated under the approved indication in Korea
Interventions
DRUGPoteligeo 20mg
Poteligeo 20mg
Sponsors
Kyowa Kirin Co., Ltd.
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Adults 19 years of age or older 2. Individuals who are confirmed to have received administration of the study drug for the purpose of the treatment for adult patients with fungoidal granuloma or Sezary syndrome who have received one or more systemic therapies, or who are considered to require administration of the study drug in the investigator's opinion 3. Individuals who (or whose legally acceptable representatives) signed the Consent to Use of Personal Information of their own free will for participation in this use-result surveillance
Exclusion criteria
1. Patients with hypersensitivity to any ingredients of this drug 2. Patients who intend to use this drug for non-approved indications 3. Patients who participated in a pre-market clinical trial of the study drug and received administration of the study drug
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety (Special situation, adverse event, symptom, or disease occurring during treatment with Poteligeo) | From first administration of Poteligeo through 90 days after the last dose | Number of participants who experience any adverse event or special situation during Poteligeo treatment and up to 90 days after the last dose, as recorded in CRFs based on medical examinations or spontaneous reports. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline to after 8th administration in Global Response Score (GRS) | Baseline (Day 1, prior to first dose) and Week 24 (after completion of 8th administration) | Change in Global Response Score (GRS) from baseline (before first dose) to after the 8th administration, assessing skin, nodes, blood, and viscera. CR/PR = Effective; SD/PD/Relapse = Ineffective. |
Countries
South Korea
Contacts
Primary ContactHaeMi Park
Outcome results
None listed